AIMZ Investment Advisors LLC Has $6.19 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

AIMZ Investment Advisors LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 66,991 shares of the biopharmaceutical company’s stock after selling 489 shares during the period. Gilead Sciences makes up 2.1% of AIMZ Investment Advisors LLC’s holdings, making the stock its 11th largest position. AIMZ Investment Advisors LLC’s holdings in Gilead Sciences were worth $6,188,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wakefield Asset Management LLLP acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $514,000. QRG Capital Management Inc. grew its position in Gilead Sciences by 7.1% in the fourth quarter. QRG Capital Management Inc. now owns 258,585 shares of the biopharmaceutical company’s stock valued at $23,885,000 after purchasing an additional 17,141 shares in the last quarter. Motiv8 Investments LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at $1,123,000. Proficio Capital Partners LLC bought a new stake in Gilead Sciences during the 4th quarter worth about $339,000. Finally, Oppenheimer & Co. Inc. lifted its position in Gilead Sciences by 0.6% during the 4th quarter. Oppenheimer & Co. Inc. now owns 286,343 shares of the biopharmaceutical company’s stock worth $26,450,000 after buying an additional 1,835 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total transaction of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 293,356 shares of company stock valued at $29,166,240 in the last ninety days. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Up 1.4 %

Shares of GILD opened at $111.99 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $112.57. The firm’s 50 day moving average is $96.98 and its 200-day moving average is $89.65. The stock has a market capitalization of $139.57 billion, a PE ratio of 302.68, a P/E/G ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.82%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Robert W. Baird lifted their target price on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. BMO Capital Markets increased their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Mizuho boosted their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Royal Bank of Canada increased their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.